Cell Source, Inc. CLCS OTC

Cell Source, Inc. (CLCS) generated $-2.68M in operating cash flow for fiscal year 2024. After capital expenditures of $0.00, free cash flow was $-2.68M.

Cash conversion ratio was 0.56x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (0/100, Fail) — weak cash flow raises concerns about debt servicing
• MOAT (28/100, Fail) — limited free cash flow weakens the competitive position
• INCOME (?/100) — Cash conversion ratio was 0.56x suggests some earnings are non-cash items

Overall SharesGrow Score: 17/100 with 0/7 criteria passed.